Supreet is the visionary behind VLife and is the architect of VLife's technology platform. With an international career of over 17 years in various senior strategic positions in large companies like Mahindra & Mahindra Ltd and Bajaj Auto Ltd, Supreet is a business development person at heart. Prior to starting VLife, Supreet was Business Strategy Advisor to Mahindra British Telecom, a technology joint venture between British Telecom plc and Mahindra & Mahindra Ltd. Developing new markets, designing and implementing business strategies and leading market linked product strategies are some of the key areas of his contribution. With business development experience in multiple geographies like the USA, Europe, Latin America, Africa and Asia, Supreet brings with him significant learning in appreciating cultural diversity and leveraging it optimally for building an efficient and result oriented organization.
Atul brings over 16 years experience in technology development in large international organizations like Fujitsu and offshore software development enterprises like Zensar Technologies Ltd. He was also associated as a strategic consultant with companies like Siemens AG and Mahindra & Mahindra Ltd. Atul shares the vision of building a technology platform that can contribute towards safer, effective and affordable drugs and make life convenient as a whole. Strong expertise in technology development coupled with an inner drive to remain at the cutting-edge has been the driving force in his illustrious career. At VLife, Atul has been a significant contributor in the evolution of VLife's technology platform. Presently he is responsible for identifying and implementing advanced technologies which facilitate complex in-silico research efforts. Having worked in India, Japan, UK and the USA, Atul brings an international outlook to business.
Discovered first multi-targeted NCE in India for Pancreatic cancer exclusively with computational technologies (now in advanced animal trials)
Credited with first New Indication discovery for Diabetic Foot Ulcer exclusivly using computational technologies (now in human trials)
Overall 11 patent pending discoveries for the clients
Innovator ofGQSAR technology - A path-breaking QSAR advancement
Innovator of VLifeScope
hybrid discovery workflow which has contributed to four discoveries